RAPT|RAPT Therapeutics Inc|Price:57.690|Chg%:0.01

More Details of RAPT Therapeutics Inc Company

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.

RAPT Therapeutics Inc Info



Ticker SymbolRAPT

Company nameRAPT Therapeutics Inc

IPO dateOct 31, 2019

CEOWong (Brian)

Number of employees68

Security typeOrdinary Share

Fiscal year-endOct 31

Address561 Eccles Ave

CitySOUTH SAN FRANCISCO

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code94080

Phone16504899000

Websitehttps://rapt.com/

Ticker SymbolRAPT

IPO dateOct 31, 2019

CEOWong (Brian)

Company Executives of RAPT Therapeutics Inc



Name

Name/Position

Position

Shareholding

Change

Dr. Mary Ann Gray, Ph.D.

Independent Director

4.96K

+4956.00%

Dr. Michael F. Giordano, M.D.

Independent Director

4.96K

+4956.00%

Ms. Linda Kozick

Independent Director

4.96K

+4956.00%

Ms. Lori Lyons-Williams

Independent Chairman of the Board

4.96K

+4956.00%

Dr. William (Bill) Ho, M.D., Ph.D.

Chief Medical Officer

--

Dr. Brian Wong, M.D., Ph.D.

President, Chief Executive Officer, Director

--

Mr. Rodney K. B. Young

Chief Financial Officer

--

Dr. Dirk Brockstedt, Ph.D.

Chief Scientific Officer

--

Dr. Scott N. Braunstein, M.D.

Independent Director

--

Dr. Ashley Dombkowski, Ph.D.

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Dr. Mary Ann Gray, Ph.D.

Independent Director

4.96K

+4956.00%

Dr. Michael F. Giordano, M.D.

Independent Director

4.96K

+4956.00%

Ms. Linda Kozick

Independent Director

4.96K

+4956.00%

Ms. Lori Lyons-Williams

Independent Chairman of the Board

4.96K

+4956.00%

Dr. William (Bill) Ho, M.D., Ph.D.

Chief Medical Officer

--

Dr. Brian Wong, M.D., Ph.D.

President, Chief Executive Officer, Director

--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.

Relevant data have not been disclosed by the company yet.

By Business

By Region

Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Mon, Nov 17

Shareholders

Shareholder Types

Shareholders

Proportion

Medicxi Ventures (UK) LLP

9.65%

Forbion Capital Partners

6.33%

TCG Crossover Management, LLC

5.65%

Foresite Capital Management, LLC

5.40%

RTW Investments L.P.

5.08%

Other

67.90%

Shareholders

Proportion

Medicxi Ventures (UK) LLP

9.65%

Forbion Capital Partners

6.33%

TCG Crossover Management, LLC

5.65%

Foresite Capital Management, LLC

5.40%

RTW Investments L.P.

5.08%

Other

67.90%

Shareholder Types

Shareholders

Proportion

Investment Advisor

17.25%

Venture Capital

16.59%

Hedge Fund

11.52%

Private Equity

9.78%

Investment Advisor/Hedge Fund

9.36%

Individual Investor

0.34%

Research Firm

0.31%

Sovereign Wealth Fund

0.04%

Other

34.79%

Institutional Shareholding



Updated: Thu, Jan 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

289

18.74M

64.73%

+113.56K

2025Q3

290

16.78M

61.62%

-1.23M

2025Q2

295

16.40M

99.19%

-1.13M

2025Q1

309

29.14M

109.47%

+11.54M

2024Q4

309

140.52M

106.54%

+100.36M

2024Q3

304

31.22M

87.82%

-13.95M

2024Q2

305

33.18M

93.85%

-9.52M

2024Q1

295

33.76M

95.60%

-5.47M

2023Q4

282

36.46M

106.02%

-3.53M

2023Q3

281

36.40M

105.98%

-3.26M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Medicxi Ventures (UK) LLP

2.79M

10.08%

--

Sep 30, 2025

Forbion Capital Partners

1.83M

6.62%

+1.49M

+432.58%

Oct 23, 2025

TCG Crossover Management, LLC

1.64M

5.9%

--

Sep 30, 2025

Foresite Capital Management, LLC

1.56M

5.64%

--

Sep 30, 2025

RTW Investments L.P.

1.47M

5.31%

--

Sep 30, 2025

The Vanguard Group, Inc.

696.19K

2.51%

-183.86K

-20.89%

Sep 30, 2025

OrbiMed Advisors, LLC

1.09M

3.92%

-555.29K

-33.82%

Sep 30, 2025

Boone Capital Management LLC

782.46K

2.82%

+782.46K

--

Sep 30, 2025

Deep Track Capital LP

751.42K

2.71%

--

Sep 30, 2025

Nantahala Capital Management, LLC

623.28K

2.25%

-328.33K

-34.50%

Sep 30, 2025

Related ETFs



Updated: Tue, Dec 2

Name

Proportion

Invesco Dorsey Wright SmallCap Momentum ETF

0.56%

Avantis US Small Cap Equity ETF

0.02%

Invesco RAFI US 1500 Small-Mid ETF

0.01%

Schwab U.S. Broad Market ETF

0%

Blueprint Chesapeake Multi-Asset Trend ETF

0%

Virtus LifeSci Biotech Clinical Trials ETF

0%

DFA Dimensional US Core Equity Market ETF

0%

iShares Russell 3000 ETF

0%

Pacer WealthShield ETF

0%

T Rowe Price Small-Mid Cap ETF

0%

Invesco Dorsey Wright SmallCap Momentum ETF

Proportion0.56%

Avantis US Small Cap Equity ETF

Proportion0.02%

Invesco RAFI US 1500 Small-Mid ETF

Proportion0.01%

Schwab U.S. Broad Market ETF

Proportion0%

Blueprint Chesapeake Multi-Asset Trend ETF

Proportion0%

Virtus LifeSci Biotech Clinical Trials ETF

Proportion0%

DFA Dimensional US Core Equity Market ETF

Proportion0%

iShares Russell 3000 ETF

Proportion0%

Pacer WealthShield ETF

Proportion0%

T Rowe Price Small-Mid Cap ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

Jun 13, 2025

Merger

8→1

Date

Ex-dividend Date

Type

Ratio

Jun 13, 2025

Merger

8→1